CYP19A1 and Parkinson disease: Thus, populations with peripheral vascular disease [22,23], Parkinson’s disease [24,25,26], aromatase inhibitor-associated arthralgia [27], chronic back pain [15], fibromyalgia [28,29], non-specific neck and shoulder pain [30], multiple sclerosis [31], in geriatric rehabilitation [32], office workers [33], and adults after COVID-19 infection [34] were investigated.